Stock zoom: Novo's plight offers a lesson on managing market expectations
Chris Hughes This maker of weight-loss drugs saw its share price zoom and then crash. The CEO has been replaced. The incoming boss will have to be careful not to let market hype get in the way of steady success. It's best to under-promise and over-deliver. Novo's blind spot has been failing to see its share price as an asset to manage—and exploit. Gift this article
Ozempic-maker Novo Nordisk saw its shares take a record plunge last week, sending their peak-to-trough collapse to 70% and returning them to levels last seen in 2022.
Ozempic-maker Novo Nordisk saw its shares take a record plunge last week, sending their peak-to-trough collapse to 70% and returning them to levels last seen in 2022.
The Danish drug giant's purpose may be to improve people's lives, but investors' shrinking gains from its opening of the anti-obesity market matter too. Novo's blind spot has been failing to see its share price as an asset to manage—and exploit.
For years, Novo had a relatively quiet life as one member of an insulin oligopoly alongside US peer Eli Lilly & Company and France's Sanofi. While it wasn't a completely smooth ride—2016 was dire—Novo has never seen operational and strategic challenges on the scale it's now facing.
In developing Ozempic for diabetes and its sibling Wegovy for weight loss, the company suddenly found itself riding a tiger.
Both firms face competition from 'compounding' copycat drugs based on similar chemistry. Shares in the more diversified Eli Lilly have held up better.
On a five-year view, Novo is still the world's third-best performing big pharma stock after Eli Lilly and Abbvie.
Perhaps if it had made a steadier journey to this point, instead of more than trebling in just over two years before its subsequent slide, there'd have been no drama. Try telling that to Lars Fruergaard Jorgensen. He has been replaced as CEO.
The giddy trajectory raises two questions related to what might grubbily be called share-price management.
First, Novo should not have let market expectations run away. At issue here was the confidence it expressed that a successor to Wegovy, CagriSema, would achieve 25% weight reduction. This long-held view within the company was expressed even a few weeks before trial data came in at 22.7% in December.
That was still impressive, but the stock market was disappointed. Its shares tumbled amid concern that the shortfall would further weaken Novo's competitive position. Company leadership is often overly preoccupied with how to get a share price up.
But boards should worry about the stock price in both directions. As the cliché goes: under-promise and over-deliver. Some may say a company can't and shouldn't try to control its share price. But that doesn't let Novo off the hook.
Should it not have taken advantage of the strength of its shares by using them as a currency to make an acquisition? That was an opportunity even before the price went into overdrive.
Novo could have diversified, say, by buying a biotech firm focused on related areas such heart disease. Instead, Novo's fortunes have yoked largely to Wegovy.
The stated objectives for the Novo investment include 'contributing positively to the lives of people" and 'generating competitive long-term financial results." That doesn't mean Novo the foundation or Novo the drugmaker ignores ordinary shareholders.
The foundation says it has an 'arm's length relationship" with Novo Nordisk, which in turn is governed by an independent board. It also says it's 'particularly mindful of observing and respecting the rights of other shareholders."
Nor has the foundation been passive. It sought the CEO change. And last year it struck a major deal to expand capacity. But the general idea that a long-term anchor shareholder is a good thing needs some qualification.
Novo's ownership structure and sheer size protect it from a takeover or shareholder activism: These are the twin threats that otherwise focus boards' attention on their stock price.
For a controlling shareholder with an indefinite investment horizon, the short-term share price—whether a bubble is inflating or deflating— is unlikely to be of much concern.
In turn, such governance is more likely a brake than a spur to doing anything opportunistic, especially if it involves issuing stock that might change the power dynamics.
Small wonder that Novo has historically avoided transformational dealmaking in favour of commercial partnerships and small bolt-ons. Also read: How Ozempic's maker lost its grip on the obesity market it created
Long-term business value determines the share price over time. In the meantime, though, markets need to be managed as much as the business. A firm's stock is a resource. New CEO Maziar Mike Doustdar says he doesn't like what happened to the share price. Maybe he gets it. ©Bloomberg Topics You May Be Interested In Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Deccan Herald
3 hours ago
- Deccan Herald
European shares rise as investors buy dips, shrug off US threats
European shares extended gains on Wednesday as investors bought into recent market weakness, brushing aside fresh U.S. tariff threats and digesting a mixed batch of corporate earnings. The pan-European STOXX 600 index was up 0.3%, as of 0713 GMT, rising for a third consecutive session after touching a five-week low on Friday. Germany's blue-chip DAX and France's CAC 40 climbed 0.5% and 0.4%, respectively. Shares of Commerzbank rose nearly 1% after the German lender posted its quarterly net profit above expectations and raised parts of its full-year outlook. Siemens Energy said it expects to hit the upper end of its 2025 growth outlook estimates. Shares rose 1.2%. Swiss President Karin Keller-Sutter was set to meet U.S. Secretary of State Marco Rubio as Switzerland seeks to negotiate the 39% tariff scheduled to take effect on Thursday. Switzerland's benchmark SMI index edged 0.1% lower. European healthcare stocks slipped 0.7%, weighed down by a 1.3% drop in heavyweight Novo Nordisk after the Danish drugmaker maintained its full-year outlook, just days after slashing its 2025 sales outlook. The Wegovy maker said it would cut costs after losing nearly $95 billion in market value last week.
Economic Times
3 hours ago
- Economic Times
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Synopsis Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sales growth, especially in the U.S. The Danish drugmaker, which lost $95 billion in market value after cutting full-year forecasts, said over one million Americans still use compounded GLP-1 drugs despite a U.S. ban. Reuters Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
Time of India
4 hours ago
- Time of India
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly , the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Affordable Pre-Owned Jewelry in Great Condition in Malaysia Rings | Search Ads Search Now Undo The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. Live Events "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
